EGFR and non-small cell lung carcinoma: Clinical trials have demonstrated anti-PD-1/anti-PD-L1 therapies can prolong overall survival in EGFR WT NSCLC patients (To et al., 2021), and chemotherapy combined with immunotherapy was approved by the United States FDA in 2020 for the treatment of metastatic or recurrent NSCLC (Shields et al., 2021).